Abivax S.A.
AAVXF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.14 | -0.34 | -0.06 | 1.99 |
| FCF Yield | -34.48% | -20.22% | -57.67% | -10.03% |
| EV / EBITDA | -2.34 | -2.17 | -2.63 | -11.98 |
| Quality | ||||
| ROIC | -110.77% | -45.59% | -95.03% | -53.18% |
| Gross Margin | 100.00% | 97.23% | 98.45% | -321.62% |
| Cash Conversion Ratio | 0.87 | 0.66 | 0.94 | 1.10 |
| Growth | ||||
| Revenue 3-Year CAGR | 33.04% | 399.86% | 589.19% | – |
| Free Cash Flow Growth | -58.85% | -40.04% | -47.04% | -53.96% |
| Safety | ||||
| Net Debt / EBITDA | 0.27 | 1.45 | -0.37 | 0.19 |
| Interest Coverage | -41.33 | -9.21 | -14.40 | -14.67 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | -0.93 | 0.01 | 0.04 |
| Cash Conversion Cycle | 529.74 | -133,535.72 | -16,240.79 | 48,201.12 |